Pleural metastases from differentiated thyroid cancer: clinical features and long-term outcomes
Authors' conclusion
PM is rare in DTC. Lack of 131I avidity, RR-DTC and more-than-moderate MPE are associated with poor OS in patients with DTC and PM.
Study context
- Population
- Patients with differentiated thyroid cancer (DTC) and pleural metastasis (PM) treated surgically and with 131I therapy, Shanghai Sixth People's Hospital, 2010–2023of 14,473 DTC
- Participants
- 27 patients
- Outcome
- OS (Kaplan-Meier)
- Follow-up
- 5-year
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Prevalence of PM in DTC
Prevalence of PM in DTC
1.87‰
27/14,473
Observational data: associations, not effects.
Further findings
Prognostic factors for worse 5-year overall survival (OS)
- More-than-moderate malignant pleural effusion (MPE)
- P = 0.031
- Lack of 131I avidity
- P = 0.041
- Radioiodine-refractory DTC (RR-DTC)
- P = 0.030
Response at end of follow-up
- Disease progression
- 8 (29.63%)
- Partial response
- 4 (14.81%)
- Complete response
- 0
- Remainder had stable disease
Mortality · end of follow-up
- Died
- 12 (44.44%)
- Survived
- 15 (55.56%)
Clinical features
- Median age at PM diagnosis (range)
- 59 years (34-79)
- No 131I avidity
- 13 (48.15%)
- RR-DTC
- 16 (59.26%)
- MPE
- 20 (74.07%)
- Large MPE
- 11 (40.74%)
- Moderate MPE
- 2
Original publication
Pleural metastases from differentiated thyroid cancer: clinical features and long-term outcomes. Eur Thyroid J. Published 10 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →